MedTrace Logo

Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery

NCT00433576 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-09-15

No results posted yet for this study

Summary

This phase I trial is studying the side effects and best dose of resveratrol in treating patients with colorectal cancer that can be removed by surgery. Resveratrol may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Adenocarcinoma of the Colon
  • Adenocarcinoma of the Rectum
  • Stage I Colon Cancer
  • Stage I Rectal Cancer
  • Stage II Colon Cancer
  • Stage II Rectal Cancer
  • Stage III Colon Cancer
  • Stage III Rectal Cancer

Interventions

DRUG

resveratrol

Given orally

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Dean Brenner · University of Michigan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-11-30
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00433576 on ClinicalTrials.gov